Michael Stegemann

1.6k total citations
34 papers, 1.1k citations indexed

About

Michael Stegemann is a scholar working on Pharmacology, Dermatology and Epidemiology. According to data from OpenAlex, Michael Stegemann has authored 34 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmacology, 9 papers in Dermatology and 7 papers in Epidemiology. Recurrent topics in Michael Stegemann's work include Antibiotics Pharmacokinetics and Efficacy (11 papers), Dermatology and Skin Diseases (9 papers) and Bacterial Identification and Susceptibility Testing (6 papers). Michael Stegemann is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (11 papers), Dermatology and Skin Diseases (9 papers) and Bacterial Identification and Susceptibility Testing (6 papers). Michael Stegemann collaborates with scholars based in United States, United Kingdom and Belgium. Michael Stegemann's co-authors include J. Sherington, Vickie L. King, Dawn M. Cleaver, J. A. WREN, SIMON E. BLANCHFLOWER, N. Schmeer, P. C. T. HANNAN, G.D. Windsor, Anno de Jong and Joseph F. Boucher and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Veterinary Microbiology and Journal of the American Veterinary Medical Association.

In The Last Decade

Michael Stegemann

33 papers receiving 1.1k citations

Peers

Michael Stegemann
Sixto M. Leal United States
Londa J. Berghaus United States
Emmanuel Bensignor France
Susana Córdoba Argentina
Christian Draing Germany
Sabine Schubert Germany
R. Aly United States
J Šinkora Czechia
Gillian Midgley United Kingdom
George J. Murakawa United States
Sixto M. Leal United States
Michael Stegemann
Citations per year, relative to Michael Stegemann Michael Stegemann (= 1×) peers Sixto M. Leal

Countries citing papers authored by Michael Stegemann

Since Specialization
Citations

This map shows the geographic impact of Michael Stegemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Stegemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Stegemann more than expected).

Fields of papers citing papers by Michael Stegemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Stegemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Stegemann. The network helps show where Michael Stegemann may publish in the future.

Co-authorship network of co-authors of Michael Stegemann

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Stegemann. A scholar is included among the top collaborators of Michael Stegemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Stegemann. Michael Stegemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gonzales, Andrea J., et al.. (2024). Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis. Journal of Veterinary Pharmacology and Therapeutics. 47(6). 447–453. 1 indexed citations
2.
Koster, Jenne De, et al.. (2021). Co‐formulation of ketoprofen with tulathromycin alters pharmacokinetic and pharmacodynamic profile of ketoprofen in cattle. Journal of Veterinary Pharmacology and Therapeutics. 45(1). 69–82. 3 indexed citations
3.
4.
5.
Cleaver, Dawn M., et al.. (2015). Long‐term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Veterinary Dermatology. 26(3). 171–171. 65 indexed citations
6.
Lees, P., Ludovic Pelligand, Jonathan Elliott, et al.. (2014). Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review. Journal of Veterinary Pharmacology and Therapeutics. 38(1). 1–14. 25 indexed citations
7.
8.
Feßler, Andrea T., Heike Kaspar, Cynthia J. Lindeman, et al.. (2011). A proposal of interpretive criteria for cefoperazone applicable to bovine mastitis pathogens. Veterinary Microbiology. 157(1-2). 226–231. 18 indexed citations
9.
Cox, Steven R., et al.. (2010). The pharmacokinetics of mavacoxib, a long‐acting COX‐2 inhibitor, in young adult laboratory dogs. Journal of Veterinary Pharmacology and Therapeutics. 33(5). 461–470. 66 indexed citations
10.
Cox, Steven R., et al.. (2010). Population pharmacokinetics of mavacoxib in osteoarthritic dogs. Journal of Veterinary Pharmacology and Therapeutics. 34(1). 1–11. 32 indexed citations
11.
Poutrel, B., et al.. (2008). Evaluation of the efficacy of systemic danofloxacin in the treatment of induced acuteEscherichia colibovine mastitis. Journal of Dairy Research. 75(3). 310–318. 30 indexed citations
12.
Six, Robert H., Dawn M. Cleaver, T. L. Skogerboe, et al.. (2008). Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. Journal of the American Veterinary Medical Association. 233(3). 433–439. 18 indexed citations
13.
Sherington, J., et al.. (2008). Efficacy and safety of cefovecin for the treatment of urinary tract infections in cats. Journal of Small Animal Practice. 49(6). 295–301. 27 indexed citations
14.
15.
Stegemann, Michael, et al.. (2007). Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. Journal of Small Animal Practice. 48(7). 378–386. 25 indexed citations
16.
Stegemann, Michael, et al.. (2007). The efficacy and safety of cefovecin in the treatment of feline abscesses and infected wounds. Journal of Small Animal Practice. 48(12). 683–689. 12 indexed citations
17.
Sherington, J., et al.. (2006). Efficacy and safety of cefovecin (Convenia™) for the treatment of urinary tract infections in dogs. Journal of Small Animal Practice. 48(3). 139–144. 19 indexed citations
18.
Stegemann, Michael, J. Sherington, & SIMON E. BLANCHFLOWER. (2006). Pharmacokinetics and pharmacodynamics of cefovecin in dogs. Journal of Veterinary Pharmacology and Therapeutics. 29(6). 501–511. 65 indexed citations
19.
Stegemann, Michael, et al.. (2006). Pharmacokinetics of cefovecin in cats. Journal of Veterinary Pharmacology and Therapeutics. 29(6). 513–524. 43 indexed citations
20.
Stegemann, Michael. (1997). Microbiology and pharmacology of enrofloxacin in cattle. The Bovine Practitioner. 76–81. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sixto M. Leal Breakdown of academic impact, for papers by Londa J. Berghaus Breakdown of academic impact, for papers by Emmanuel Bensignor Breakdown of academic impact, for papers by Susana Córdoba Breakdown of academic impact, for papers by Christian Draing Breakdown of academic impact, for papers by Sabine Schubert Breakdown of academic impact, for papers by R. Aly Breakdown of academic impact, for papers by J Šinkora Breakdown of academic impact, for papers by Gillian Midgley Breakdown of academic impact, for papers by George J. Murakawa
Rankless by CCL
2026